Please login to the form below

Not currently logged in
Email:
Password:

Philadelphia chromosome positive acute lymphoblastic leukaemia

This page shows the latest Philadelphia chromosome positive acute lymphoblastic leukaemia news and features for those working in and with pharma, biotech and healthcare.

EMA to review safety of Ariad’s Iclusig

EMA to review safety of Ariad’s Iclusig

The PRAC also recommend that the product information be updated for Iclusig, which was approved in the EU in July to treat patients with chronic myeloid leukaemia (CML) and Philadelphia-chromosome ... positive acute lymphoblastic leukaemia (Ph+ ALL).

Latest news

  • Ariad cuts 160 jobs in US after Iclusig suspension Ariad cuts 160 jobs in US after Iclusig suspension

    The authorisations cover use of the drug to treat adults with advanced forms of chronic myeloid leukaemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL).

  • FDA suspends sale of Ariad’s cancer drug FDA suspends sale of Ariad’s cancer drug

    Iclusig linked to increased risk of blood clots. The US Food and Drug Administration (FDA) has asked Ariad to suspend sales of its leukaemia drug Iclusig as it continues to investigate ... accelerated phase, or blast phase CML or Philadelphia

  • Ariad tanks as Iclusig trial is halted on safety grounds Ariad tanks as Iclusig trial is halted on safety grounds

    The EPIC trial involved patients with newly-diagnosed chronic myeloid leukaemia (CML) and was stopped "in the interest of patient safety", said the company in a statement. ... accelerated phase, or blast phase CML or Philadelphia chromosome-positive

  • Ariad halts patient enrolment for cancer drug studies Ariad halts patient enrolment for cancer drug studies

    Iclusig (ponatinib) received early approval in the US last year for the treatment of advanced chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), under the proviso

  • Ariad gets EU green light for leukaemia drug Iclusig Ariad gets EU green light for leukaemia drug Iclusig

    The EC gave the go-ahead for Iclusig (ponatinib) as another treatment option for patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... Japan. Meanwhile, it is also focusing on

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    December 2012 for its use in two rare types of cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... As for the future of Iclusig in leukaemia, Ariad is keen to roll out the drug in

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Ariad founder Harvey Berger to retire as CEO and chairman Ariad founder Harvey Berger to retire as CEO and chairman

    Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,

  • Hugh Cole leaves Shire for Ariad Hugh Cole leaves Shire for Ariad

    This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
fox&cat

up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....